BPI
CYTK icon

BFC Planning, Inc.’s Cytokinetics CYTK Stock Holding History

BFC Planning, Inc.’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.13K Buy
72
+9
+14% +$646 ﹤0.01% 2600
2026
Q1 		$4.15K Sell
63
-6
-9% -$381 ﹤0.01% 2379
2025
Q4 		$4.38K Buy
69
+16
+30% +$995 ﹤0.01% 2399
2025
Q3 		$2.91K Buy
53
+12
+29% +$494 ﹤0.01% 2365
2025
Q2 		$1.36K Hold
41
– – ﹤0.01% 2389
2025
Q1 		$1.65K Buy
41
+14
+52% +$643 ﹤0.01% 2343
2024
Q4 		$1.27K Buy
+27
New +$1.4K ﹤0.01% 2368

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

BFC Planning, Inc.'s CYTK Position: Q2 2026 in Review

BFC Planning, Inc. increased its Cytokinetics (CYTK) stake by 14% in Q2 2026, buying an estimated $646 and bringing the position to 72 shares worth $6.13K. The position accounts for ﹤0.01% of the portfolio, ranked #2600.

BFC Planning, Inc. first reported a position in CYTK in Q4 2024 and has held it in 7 quarters since. 486 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • BFC Planning, Inc. held 72 shares of Cytokinetics worth $6.13K as of Q2 2026.
  • BFC Planning, Inc. bought 9 Cytokinetics shares in Q2 2026, an estimated $646.
  • Cytokinetics made up ﹤0.01% of BFC Planning, Inc.'s portfolio in Q2 2026, its #2600 holding.
  • BFC Planning, Inc. first reported a position in Cytokinetics in Q4 2024 and has held it in 7 quarters since.
  • 486 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on BFC Planning, Inc.'s 13F filing for Q2 2026, filed 29 Oct 2026.